ELISA-Entwicklung GmbH & Co. KG

            Deutsch        English                     Home        Service        Contact        Links        Company        Publications

 
     Range of Services
     Assay Development
     Assay Validation
     Sample Measurement
     Protein Purification
     Antibody Production
     HCP-Assays
     Anti Drug Antibody, ADA
     Testkits

 

 
 

Host Cell Protein (HCP)

Challenges of Monitoring Host Cell Protein Impurities

Recombinant protein pharmaceuticals have to be purified to a high degree from host cell components to avoid adverse drug effects like allergic or anaphylactic reactions. Typically a multianalyte enzyme-linked immunosorbent assay (ELISA) is the method of choice, using polyclonal antibodies to fulfil the following features:
-  A simple validated method
-  High sensitivity to find trace amounts in a final drug substance
-  Exact reproducible quantification
-  Recognition of a wide number of epitopes present in the impurities

Options to increase HCP recognition

  • Utilisation of Polyclonal antibodies instead of monoclonal
  • Usage of a mix of antibodies of different host species (e.g. goat and rabbit),
  • Protein A purified antibodies instead of specifically HCP purified antibodies for additional measurement of epitopes with low antigenity,
  • Streptavidin coated plates instead of direct antibody coating to reduce antibody denaturation,
  • Mix of differently conjugated antibodies to biotin and HRP (antibody linked via lysine and via cysteine),
  • Test performance with only one incubation step to reduce antigen loss of low-affinity antibodies

Principle of a HCP ELISA

  • an excess of streptavidin coating reduces well to well variation and unspecific background
  • indirect antibody coating via streptavidin avoids AB binding site denaturation which occurs during direct AB coating
  • indirect AB coating increases sensitivity by reducing steric hindrance
  • direct AB-enzyme conjugation allows a 1-step incubation assay protocol to reduce dissociation of low affinity AB
  • using a combination of Cys- and Lys-linked AB increases antigen binding

Optional established methods supporting HCP assay development

  • Organization and supervision of antibody production
  • Antiserum screening, purification and conjugate syntheses
  • 1D and 2D electrophoresis with silver staining for HCP visualization
  • Western blotting for demonstration of antibody binding and specifity
  • Assay development, validation, documentation and test kit production
  • Technology transfer and adaptation at customer lab including training of responsible persons
  • Adaptation to automatic systems if desired